Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.

Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M, Boone C, Carré D, Kalinichev M, Lezmi S, Mir I, Nicoleau C, Palan S, Perier C, Raban E, Zhang S, Dong M, Stenmark P, Krupp J.

Sci Adv. 2019 Jan 16;5(1):eaau7196. doi: 10.1126/sciadv.aau7196. eCollection 2019 Jan.

2.

Immaterial and monetary gifts in economic transactions: evidence from the field.

Kirchler M, Palan S.

Exp Econ. 2018;21(1):205-230. doi: 10.1007/s10683-017-9536-1. Epub 2017 Aug 2.

3.

Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.

Elliott M, Maignel J, Liu SM, Favre-Guilmard C, Mir I, Farrow P, Hornby F, Marlin S, Palan S, Beard M, Krupp J.

PLoS One. 2017 Oct 5;12(10):e0185628. doi: 10.1371/journal.pone.0185628. eCollection 2017.

4.

Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors.

Tao L, Peng L, Berntsson RP, Liu SM, Park S, Yu F, Boone C, Palan S, Beard M, Chabrier PE, Stenmark P, Krupp J, Dong M.

Nat Commun. 2017 Jul 3;8(1):53. doi: 10.1038/s41467-017-00064-y.

5.

GIMS-Software for asset market experiments.

Palan S.

J Behav Exp Finance. 2015 Mar;5:1-14.

6.

A Good Beginning Makes a Good Market: The Effect of Different Market Opening Structures on Market Quality.

Hinterleitner G, Leopold-Wildburger U, Mestel R, Palan S.

ScientificWorldJournal. 2015;2015:307808. doi: 10.1155/2015/307808. Epub 2015 Aug 13.

7.

Why and How Maxillofacial Disability and Impairment Due to Trauma Should be Quantified for Compensation: A Need for Nationwide Guidelines.

Shah N, Palan S, Mahajan A, Shah P, Shah R, Kumar P.

J Maxillofac Oral Surg. 2014 Dec;13(4):425-30. doi: 10.1007/s12663-013-0527-2. Epub 2013 May 19.

8.

Bimaxillary presentation of central ossifying fibroma: a unique aggressive entity.

Desai K, Gupta K, Manjunatha BS, Palan S.

BMJ Case Rep. 2013 Jun 16;2013. pii: bcr2013010124. doi: 10.1136/bcr-2013-010124.

9.

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.

Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J.

J Med Chem. 2012 Feb 9;55(3):1021-46. doi: 10.1021/jm201310y. Epub 2012 Jan 27.

PMID:
22224594
10.

High-resolution crystal structure of human Mapkap kinase 3 in complex with a high affinity ligand.

Cheng R, Felicetti B, Palan S, Toogood-Johnson I, Scheich C, Barker J, Whittaker M, Hesterkamp T.

Protein Sci. 2010 Jan;19(1):168-73. doi: 10.1002/pro.294.

11.

Clinical safety and efficacy of first indigenous recombinant hepatitis B vaccine.

Kumar A, Joshi N, Sreenivas DV, Palan S, Nagarjuna Kumar YR.

J Assoc Physicians India. 1998 Jul;46(7):620-2.

PMID:
12152846
12.

Antibacterial activities and characterization of novel inhibitors of LpxC.

Clements JM, Coignard F, Johnson I, Chandler S, Palan S, Waller A, Wijkmans J, Hunter MG.

Antimicrob Agents Chemother. 2002 Jun;46(6):1793-9.

13.

Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.

Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, Thomas W, Whittaker M, Wood S, Salama S, Baker PJ, Rodgers HF, Barynin V, Rice DW, Hunter MG.

Antimicrob Agents Chemother. 2001 Feb;45(2):563-70.

14.

Safety and immunogenicity of indigenous recombinant hepatitis B vaccine (Shanvac-B) in comparison with commercially available vaccine.

Joshi N, Kumar A, Sreenivas DV, Palan S, Nagarjuna Kumar YR.

Indian J Gastroenterol. 2000 Apr-Jun;19(2):71-3.

PMID:
10812819
15.

Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants.

Czaplewski LG, McKeating J, Craven CJ, Higgins LD, Appay V, Brown A, Dudgeon T, Howard LA, Meyers T, Owen J, Palan SR, Tan P, Wilson G, Woods NR, Heyworth CM, Lord BI, Brotherton D, Christison R, Craig S, Cribbes S, Edwards RM, Evans SJ, Gilbert R, Morgan P, Randle E, Schofield N, Varley PG, Fisher J, Waltho JP, Hunter MG.

J Biol Chem. 1999 Jun 4;274(23):16077-84.

16.

An infectious hepatitis epidemic in a small town in 1964.

Masár I, Roda J, Palan S, Kossár M, Kristofík A.

J Hyg Epidemiol Microbiol Immunol. 1965;9(3):387-96. No abstract available.

PMID:
5893327
17.

[POLLUTION OF ATMOSPHERE IN THE AREA OF ENO PLANT].

PALAN S.

Cesk Hyg. 1963 Jul;8:364-71. Czech. No abstract available.

PMID:
14077291

Supplemental Content

Support Center